Clinical-stage biopharmaceutical company CuraSen Therapeutics has treated the first subject in the Phase I trial of CuraAX to treat neurogenic orthostatic hypotension (nOH). The trial aims to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback